247 related articles for article (PubMed ID: 22833612)
21. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
[TBL] [Abstract][Full Text] [Related]
22. Patterns of use and health expenses associated with triptans among adults with migraines.
Wu J; Noxon V; Lu ZK
Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
[TBL] [Abstract][Full Text] [Related]
23. A Brief Look at Urgent Care Visits for Migraine: The Care Received and Ideas to Guide Migraine Care in this Proliferating Medical Setting.
Minen MT; Zhou K; Miller L
Headache; 2020 Mar; 60(3):542-552. PubMed ID: 31802490
[TBL] [Abstract][Full Text] [Related]
24. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
Lee JH; Shewale AR; Barthold D; Devine B
Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
[TBL] [Abstract][Full Text] [Related]
25. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
[TBL] [Abstract][Full Text] [Related]
26. Treatment persistence and switching in triptan users: a systematic literature review.
Messali AJ; Yang M; Gillard P; Tsai K; Tepper SJ; Bloudek LM; Kori SH
Headache; 2014; 54(7):1120-30. PubMed ID: 24912394
[TBL] [Abstract][Full Text] [Related]
27. Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis.
Roessler T; Zschocke J; Roehrig A; Friedrichs M; Friedel H; Katsarava Z
J Headache Pain; 2020 Jul; 21(1):85. PubMed ID: 32631274
[TBL] [Abstract][Full Text] [Related]
28. Risk of ischemic complications related to the intensity of triptan and ergotamine use.
Wammes-van der Heijden EA; Rahimtoola H; Leufkens HG; Tijssen CC; Egberts AC
Neurology; 2006 Oct; 67(7):1128-34. PubMed ID: 17030745
[TBL] [Abstract][Full Text] [Related]
29. The risk of newly diagnosed asthma in migraineurs with or without previous triptan prescriptions.
Becker C; Brobert GP; Almqvist PM; Johansson S; Jick SS; Meier CR
Headache; 2008 Apr; 48(4):606-10. PubMed ID: 18194300
[TBL] [Abstract][Full Text] [Related]
30. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
[TBL] [Abstract][Full Text] [Related]
31. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
[TBL] [Abstract][Full Text] [Related]
32. [The Vigimig study of naratriptan use in general practice].
Lanteri-Minet M; Nachit-Ouinekh F; Druais PL; Allaert FA; El Hasnaoui A
Presse Med; 2007 Nov; 36(11 Pt 1):1536-44. PubMed ID: 17664053
[TBL] [Abstract][Full Text] [Related]
33. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
34. Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey--phase IV.
MacGregor EA; Brandes J; Gendolla A; Giammarco R
Curr Med Res Opin; 2004 Nov; 20(11):1777-83. PubMed ID: 15537478
[TBL] [Abstract][Full Text] [Related]
35. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
[TBL] [Abstract][Full Text] [Related]
36. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
37. Intensive community pharmacy intervention had little impact on triptan consumption: a randomized controlled trial.
Søndergaard J; Foged A; Kragstrup J; Gaist D; Gram LF; Sindrup SH; Muckadell HU; Larsen BO; Herborg H; Andersen M
Scand J Prim Health Care; 2006 Mar; 24(1):16-21. PubMed ID: 16464810
[TBL] [Abstract][Full Text] [Related]
38. Triptan education and improving knowledge for optimal migraine treatment: an observational study.
Baron EP; Markowitz SY; Lettich A; Hastriter E; Lovell B; Kalidas K; Dodick DW; Schwedt TJ;
Headache; 2014 Apr; 54(4):686-97. PubMed ID: 24520930
[TBL] [Abstract][Full Text] [Related]
39. Triptans--why once?
Ifergane G; Wirguin I; Shvartzman P
Headache; 2006 Sep; 46(8):1261-3. PubMed ID: 16942470
[TBL] [Abstract][Full Text] [Related]
40. Public Drug Coverage and Its Impact on Triptan Use Across Canada: A Population-Based Study.
Amadio A; Lee K; Yao Z; Camacho X; Knowles S; Lay C; Paterson JM; Hunt J; Gomes T;
Headache; 2015; 55 Suppl 4():212-20. PubMed ID: 25754431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
